Literature DB >> 3789582

NIH conference. Lupus nephritis.

J E Balow, H A Austin, G C Tsokos, T T Antonovych, A D Steinberg, J H Klippel.   

Abstract

Nephritis has long been considered one of the most ominous components of systemic lupus erythematosus. Accumulations of immune complexes and lymphoid cells in several locations within the kidney are the best-described elements of lupus nephritis. The extreme diversity of the renal changes indicates that many variables are likely to be involved. Inbred strains of lupus-prone mice have provided homogeneous subjects for study of pathogenesis and response to treatment. Comparable grouping of lupus nephritis in humans according to unique or dominant pathogenetic mechanisms is imprecise and limited by insufficient knowledge of the primary stimulus for the disease. Treatment is also imperfect and, at times, hazardous. Certain regimens incorporating cytotoxic drugs provide a significant therapeutic advantage over corticosteroids alone in the management of this disease.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3789582     DOI: 10.7326/0003-4819-106-1-79

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  22 in total

Review 1.  Systemic lupus erythematosus.

Authors:  M S Klein-Gitelman; M L Miller
Journal:  Indian J Pediatr       Date:  1996 Jul-Aug       Impact factor: 1.967

Review 2.  Clinical immunology.

Authors:  R J Powell
Journal:  Postgrad Med J       Date:  1991-11       Impact factor: 2.401

Review 3.  Kidney disease in systemic lupus erythematosus.

Authors:  J E Balow
Journal:  Rheumatol Int       Date:  1991       Impact factor: 2.631

4.  Analysis of T cells and major histocompatibility complex class I and class II mRNA and protein content and distribution in antiglomerular basement membrane disease in the rabbit.

Authors:  C Eldredge; S Merritt; M Goyal; H Kulaga; T J Kindt; R Wiggins
Journal:  Am J Pathol       Date:  1991-11       Impact factor: 4.307

5.  Immunosuppressive treatment in severe connective tissue diseases: effects of low dose intravenous cyclophosphamide.

Authors:  I Martin-Suarez; D D'Cruz; M Mansoor; A P Fernandes; M A Khamashta; G R Hughes
Journal:  Ann Rheum Dis       Date:  1997-08       Impact factor: 19.103

6.  Auricular chondritis and diffuse proliferative glomerulonephritis in primary Sjögren's syndrome.

Authors:  M A Rodriguez; F J Tapanes; I L Stekman; J A Pinto; O Camejo; I Abadi
Journal:  Ann Rheum Dis       Date:  1989-08       Impact factor: 19.103

Review 7.  The treatment of lupus nephritis.

Authors:  J S Cameron
Journal:  Pediatr Nephrol       Date:  1989-07       Impact factor: 3.714

8.  The favourable effect of cyclophosphamide pulse therapy in the treatment of massive pulmonary haemorrhage in systemic lupus erythematosus.

Authors:  M Fukuda; Y Kamiyama; K Kawahara; K Kawamura; T Mori; M Honda
Journal:  Eur J Pediatr       Date:  1994-03       Impact factor: 3.183

9.  Systemic lupus erythematosus in Saudi patients.

Authors:  S R Alballa
Journal:  Clin Rheumatol       Date:  1995-05       Impact factor: 2.980

10.  Immunomodulation of autoimmunity in MRL/lpr mice with syngeneic bone marrow transplantation (SBMT).

Authors:  D M Karussis; U Vourka-Karussis; D Lehmann; O Abramsky; A Ben-Nun; S Slavin
Journal:  Clin Exp Immunol       Date:  1995-04       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.